Articles On NeuroScientific Biopharmaceuticals (ASX:NSB)

ShareCafeLunch Report: 15 June, 2022 The Australian sharemarket has extended its fall for a fourth straight day with consumer staples and utilities advancing while the other sectors are in the red. Healthcare is the worst performer while th...

15 Jun 2022 - A snapshot of the stocks on the move featuring NeuroScientific Biopharmaceuticals (ASX:NSB), Lithium Plus Minerals (ASX:LPM) & Bluglass (ASX:BLG).

Neuroscientific announce positive results of EmtinB in mice model Island Pharma appoints new drug manufacturer for Phase 2 study Neuroscientific announces positive results for EmtinB NeuroScientific Biopharmaceuticals (ASX: NSB) has annou...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

NeuroScientific Biopharmaceuticals (NSB) reports “positive” preliminary results from an animal study for multiple sclerosis The study evaluated NSB’s lead drug candidate, EmtinB, across four dose groups in a mouse model, with the drug admi...

Highlights The HREC gave a green signal to NeuroScientific for conducting an early-phase clinical trial of its lead drug candidate. The trial will evaluate the biomarkers in human blood samples that provide proof for the working mechan...

Orthocell’s nerve reconstruction trial shows encouraging results Neuroscientific gets ethics approval to commence early-phase clinical trial Orthocell demonstrates encouraging trial results Orthocell (ASX:OCC) jumped 7% this morning after...

NeuroScientific Biopharmaceuticals (ASX:NSB) has submitted an application seeking approval for an early-phase clinical trial involving its lead drug candidate EmtinB.

IDX snaps up QLD-based radiology group for circa $38m  NSB starts HREC review process  Credit Suisse downgrades HLS, initiates coverage of ACL   Integral Diagnostics Limited (ASX:IDX) says it’s agreed to terms with Queensland-based Exact...

NeuroScientific Biopharmaceuticals (NSB) is on schedule to begin the clinical development of its lead drug candidate, EmtinB, in the first half of 2022 The company today has submitted an application for an early-phase clinical trial involv...

NeuroScientific Biopharmaceuticals (ASX:NSB) has reported positive outcomes from its preclinical safety and toxicology program involving its lead drug candidate EmtinB.

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

NeuroScientific Biopharmaceuticals (NSB) confirms the safety of its lead drug candidate, EmtinB The company has seen positive outcomes from its preclinical safety and toxicology program to support commencement of first in-human clinical tr...

Okay, who poked the S&P/ASX Emerging Companies index (XEC) this morning? Someone woke the sleeping Spinosaurus – the largest carnivorous dinosaur on this planet – that lies at the heart of our beloved small cap thermometer. It started r...

Oncosil’s medical device is being used commercially for the first time in Europe NeuroScientific Biopharma is set to commence Phase 1 clinical trial after a successful toxicology study Medical device company, OncoSil Medical (ASX:OSL), su...

NeuroScientific Biopharmaceuticals (NSB) completes an assessment of its lead drug candidate EmtinB for reducing inflammation in autoimmune diseases EmtinB significantly reduced inflammatory growth proteins, or cytokines, which are closely...

ASX to fall, US inflation highest in 40 years US inflation soared to 7.9% in the past year, outpacing the 7.5% year-on-year recorded last month as it hits a new 40-year high. The high CPI is expected to keep the Fed’s plan to hike rates, sl...

Neurotech International (NTI) appoints Alexandra Andrews as Chief Executive Officer (CEO), effective from Tuesday, next week Dr Andrews has experience in corporate development, investor engagement, product development and commercialisation...

NeuroScientific Biopharmaceuticals (ASX:NSB) share price jumped ~13% today to 35 cents after an update on its lead drug candidate EmtinB. The company said it has executed on the successful completion of invitro genotoxicity and plasma prote...

NeuroScientific Biopharmaceuticals (NSB) completes two studies involving its lead drug candidate, EmtinB The completion of in-vitro genotoxicity and plasma protein binding studies comes in the lead up to the start of first-in-human Phase 1...

NeuroScientific Biopharmaceuticals (ASX:NSB) has reported outcomes from recently completed in vitro genotoxicity studies and plasma protein binding studies involving its lead drug candidate EmtinB.

ASX to open flat amid late sell off in US tech Wall Street mainly finished lower on Monday as a late selloff drove tech stocks down. In the last hour of trading, heavy selling volumes saw the Nasdaq falling by 0.58% as investors ditched big...

The price action of ASX biotech shares was nothing short of a mixed bag in 2021. Several of the majors underperformed the benchmark S&P/ASX 200 Pharmaceuticals & Biotechnology index (AXPBJD), whereas many small-cap names came thro...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price is rising today on the back of a clinical trial update. Shares in the company are trading at 34 cents at the time of writing, up 11.48%. Let’s take a look at what may be we...

The ASX 200 Health Index (XHJ) is trading higher by 0.70% at the time of writing, compared to the broader index which is up by 0.55%. OncoSil Medical (ASX:OSL) has released the final results of the PanCO clinical study for the treatment of...

NeuroScientific Biopharmaceuticals (NSB) reports positive results from off-target safety assessment of its lead drug candidate EmtinB EmtinB is a drug targeted at neurodegenerative conditions which affect the central nervous system such as...

Wall Street gains for third consecutive day US stocks staged a pre-Christmas rally as omicron fears eased, with the S&P 500 nearing its record high. All three major US stockmarket indexes rose overnight – the S&P 500 by 0.62%, Dow J...

ShareCafeWebinar Recap – ECT, ATV, TZL, AO1 Catch up on the full webinar with presentations from Environmental Clean Technologies (ASX: ECT),  ActivePort (ASX: ATV), TZ Limited (ASX: TZL) & NeuroScientific Biopharmaceuticals (ASX: NSB)...

ShareCafeNeuroScientific Biopharmaceuticals (ASX: NSB) – Webinar Presentation Alexandra Andrews – Director Of Operations – Neuroscientific Biopharmaceuticals is developing novel peptide-based pharmaceutical products that target a number o...

It’s been a busy morning for the ASX Healthcare sector, with plenty of positive announcements for investors to digest. But the Health Index (XHJ) is trading down by 0.5% at the time of writing, compared to the broader index which is trading...

The broad Australian indices have started the day off in the red as the market resets from a number of stirrups this week. The S&P/ASX 200 index (ASX: XJO) has clipped 0.37% lower today and sits at 7,343 points, whereas the S&P/AS...

ShareCafeHidden Gems Webinar Recap – CYP, AT1, NSB & KZA Catch up on the full webinar with presentations from Cynata Therapeutics (ASX: CYP), Atomo Diagnostics (ASX: AT1), NeuroScientific (ASX: NSB) & Kazia Therapeutics (ASX: KZA)...

ShareCafePeptide based therapies for neurodegenerative conditions Dougal Thring  – VP Clinical Development – NeuroScientific Biopharmaceuticals is developing novel peptide-based pharmaceutical products that target a number of neurologi...

Neurological disorder specialist, Neuroscientific Biopharma (ASX:NSB), announced that research work on its lead drug EmtinB has received a tax incentive rebate under the R&D Tax Incentive program. The company said that it has been grant...

The breakthrough announcement by NeuroScientific Biopharma today elevates its lead drug EmtinB to hunt down the $20bn multiple sclerosis market. Australian drug development company NeuroScientific Biopharmaceuticals (ASX:NSB) announced that...

S&P 500 and Nasdaq at record highs again The US stock markets are coming home for a strong finish in August, with both the S&P 500 and Nasdaq lifting to record highs. The S&P 500 rose by 0.43%, the Nasdaq by 0.9%, but the Dow Jo...

Leading the health stocks today is Nanosonics (ASX:NAN)  up 19.69% after flagging FY21 revenues of $103.1 million, with strong momentum in H2 where revenues came in at $60 million – up 39% from H1. The company installed 3,030 units of its a...

Another red day for the ASX to close out the week. The ASX 200 closed 0.05% down from yesterday at 7,461 points, 2.2% lower than a week ago. The ASX Emerging Companies Index meanwhile dropped 2.09%, closing at 2,187 points which is over 5%...

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price jumped higher this morning before becoming subject to a trading halt at lunchtime. Before the pause in trading, the Australian biotech company’s shares were exchanging hand...

The broader ASX continued its losing streak, shedding another 0.5% while the benchmark ASX 200 closed at 7,465 points, which is 2.2% lower than last Friday’s close. Health and consumer discretionary goods were rays of sunshine with gains of...

Got 90 seconds? Then listen to Chairman, Paul Rennie tell us about their company news. Neuroscientific biopharmaceuticals (ASX:NSB) is an Australian biotechnology company developing novel disease modifying therapies for neurodegenerative di...

It wasn’t a happy start to the new financial year for Australia’s bourse, which lost nearly two thirds of one per cent today. Likewise, the ASX200, which rose 22% in FY21, closed down 0.65% to 7,266. Meanwhile, the ASX Emerging Companies In...

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) shares jumped more than 7% in early trade after the company released the readouts for the successful completion of its pivotal ocular safety study. Since then, however, the NeuroScientific...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

23 Jun 2021 - A snapshot of notable stock news for the hour, featuring ikeGPS Group, Wide Open Agriculture, Respiri & NeuroScientific Biopharmaceuticals.

23 Jun 2021 - NeuroScientific Biopharmaceuticals (ASX:NSB) has partnered with Linear Clinical Research to commence Phase 1 clinical trials for its lead drug candidate EmtinB.

Summary The ASX 200 traded lower by 27.30 points or 0.37% at 7,314.90 by afternoon, led by energy and banking stocks. Nine out of 11 sectoral indices were trading in the red, barring tech and materials. CBA expects the Reserve Bank of...

NeuroScientific Biopharmaceuticals (ASX:NSB) edged even closer to a planned Phase I clinical trial of EmtinBTM. The company has found a research partner in Perth-based Linear Clinical Research. Linear operates a clinical trials facility on...